DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Jackisch C, Stroyakovskiy D, Pivot X. et al
Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH phase 3 randomized clinical trial.
JAMA Oncol 2019;
5 (05) e190339
We do not assume any responsibility for the contents of the web pages of other providers.